Recently, whole exome sequencing (WES) analyses in multiple myeloma (MM) [2–5], albeit reporting slightly higher mutational frequencies (probably for the extension of the analysis to the entire coding sequence and the greater sensitivity), confirmed the findings of the early studies [6–10], i.e. that TP53 mutations are relatively rare at presentation (mutation prevalence ranging from 0% to 9.7% in representative MM patients' cohorts). The gene discussed is TP53; the disease is plasma cell myeloma.